BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Athersys, Inc. 

3201 Carnegie Avenue

Cleveland  Ohio  44115  U.S.A.
Phone: 216-431-9900 Fax: 216-361-9495


SEARCH JOBS




Industry
Biotechnology


Collaborations

Elan Corporation PLC  A joint venture to develop and commercialize a specific therapeutic protein. Athersys is contributing the protein production capabilities of its RAGE technology and Elan is contributing a proprietary drug delivery technology.

Medarex, Inc.  A collaboration to develop novel therapeutics produced through the joint application of Medarex's HuMAb Mouse® technology and Athersys' RAGE technology. The companies plan to jointly discover, develop and commercialize fully human antibodies as therapeutics.

Acorda Therapeutics  A functional genomics collaboration focused on the discovery of validated drug targets to treat certain central nervous system disorders, including spinal cord injuries and multiple sclerosis. Athersys and Acorda will jointly own therapeutic products or validated targets identified and developed through the collaboration.

University of Alabama at Birmingham  A collaboration to jointly conduct high-throughput structural analysis of validated drug targets.

University of Rochester  A research collaboration with Dr. Mark Noble of the University of Rochester under a Phase I SBIR Grant to Athersys to discover and validate novel CNS drug targets.

Molecumetics  Athersys will provide Molecumetics with cell lines expressing up to 12 validated drug targets produced using the RAGE-Validated Targets technology. Molecumetics plans to use its chemistry based "screen-to-IND" technology platform to develop novel small molecule drug candidates against the validated targets. Targets may be licensed by Molecumetics or co-developed with Athersys.

Cleveland Clinic  A collaboration to discover and functionally validate novel drug targets that play an important role in cancer and inflammation. Athersys scientists will work with researchers under the direction of Dr. George R. Stark, Chairman of the Lerner Research Institute at CCF, to rapidly and efficiently identify novel drug targets that regulate certain cell-signaling and disease pathways. Athersys has an exclusive option to commercialize novel therapeutics that result from the collaboration.

Bristol-Myers Squibb Company  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Center for Stem Cell and Regenerative Medicine  is a Founding member of CSCRM and is actively developing therapeutics based on the Multipotent Adult Progenitor Cell (MAPC) technology, originally developed by Dr. Catherine Verfaillie and colleagues at the University of Minnesota and licensed exclusively to Athersys. The company has numerous collaborations with CSCRM investigators and institutions to rapidly advance its product candidates to the clinic.





 Company News
Athersys, Inc. (ATHX) Reports Second Quarter 2014 Results 8/11/2014 5:18:34 PM
Athersys, Inc. (ATHX) To Host Second Quarter 2014 Financial Results Call 7/16/2014 11:01:01 AM
Athersys, Inc. (ATHX) Reports First Quarter 2014 Results 5/9/2014 8:53:27 AM
Athersys, Inc. (ATHX)'s Stem Cell Therapy For Bowel Disease Flops In Phase 2 Study 4/28/2014 8:48:28 AM
Athersys, Inc. To Host First Quarter 2014 Financial Results Call 4/17/2014 9:24:07 AM
Athersys, Inc. To Present At 2014 Biotechnology Industry Organization (BIO) Asia International Conference 3/27/2014 9:19:08 AM
Athersys, Inc. Files Shelf Registration Statement To Replace Prior Shelf 3/14/2014 9:47:43 AM
Athersys, Inc. Reports Fourth Quarter And 2013 Annual Results 3/14/2014 9:18:02 AM
Athersys, Inc. To Present At Regen Med Investor Day March 26th In New York 3/10/2014 9:45:58 AM
Athersys, Inc. To Host Fourth Quarter And Annual Financial Results Call 2/25/2014 9:08:44 AM
12345678910...